Healthcare / BiotechnologyTaipei Exchange
$96.70
+0.30 (+0.31%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $283.7M · quality 53.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.6B
P/E
9.7x
↓EV/EBITDA
5.8x
↓ROE
11.4%
↑Gross Margin
33.9%
↓Debt/Equity
0.13
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+3.4%
FCF CAGR
—
FCF margin
11.4%
FCF / Net income
0.89x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.14B · net income $271.6M · FCF $243.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.14B | $2.14B | $2.01B | $1.84B | $1.93B |
| Net Income | $271.6M | $271.6M | $240.2M | $274.8M | $321.2M |
| EBITDA | $461.8M | $461.8M | $423.6M | $442.1M | $488.0M |
| EPS | — | — | 8.85 | 10.13 | 11.84 |
| Gross Margin | 33.9% | 33.9% | 36.0% | 35.0% | 35.6% |
| Operating Margin | 15.2% | 15.2% | 15.4% | 16.0% | 19.7% |
| Net Margin | 12.7% | 12.7% | 11.9% | 15.0% | 16.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.13 | 0.13 | 0.24 | 0.32 | 0.39 |
| Current Ratio | 1.84 | 1.84 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $243.1M | $243.1M | $283.7M | $321.3M | $-307.2M |
| Returns | |||||
| ROE | 11.4% | 11.4% | 10.7% | 12.9% | 16.1% |
| Valuation | |||||
| P/E | 9.66 | 9.66 | 14.41 | 15.00 | 13.77 |
| EV/EBITDA | 5.76 | 5.76 | 8.64 | 10.04 | 10.17 |
| P/B | 1.10 | 1.10 | 1.55 | 1.93 | 2.22 |
| Growth & Yield | |||||
| Revenue Growth | 6.1% | 6.1% | 9.6% | -4.8% | — |
| EPS Growth | — | — | -12.6% | -14.4% | — |
| Dividend Yield | 5.2% | 5.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-24.2%
Start / end P/E
n/dx → n/dx
EPS bridge
8.85 → n/d
Residual
-29.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.